Summit Therapeutics

Q2 FY2026 EarningsQ2 FY2026 GAAP net loss narrowed to $215.7M from $565.7M YoY, primarily due to a $410.1M decrease in stock-based compensation expense. Non-GAAP operating expenses rose to $151.8M (+69.4% YoY) driven by aggressive clinical expansion of Ivonescimab. Cash reserves reached $690.7M, bolstered by $230.8M in ATM proceeds. Key catalyst: FDA PDUFA date for Ivonescimab in EGFRm NSCLC is set for November 14, 2026.